JP2006514549A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006514549A5 JP2006514549A5 JP2004563586A JP2004563586A JP2006514549A5 JP 2006514549 A5 JP2006514549 A5 JP 2006514549A5 JP 2004563586 A JP2004563586 A JP 2004563586A JP 2004563586 A JP2004563586 A JP 2004563586A JP 2006514549 A5 JP2006514549 A5 JP 2006514549A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- antigen
- immune response
- animal
- administration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000427 antigen Substances 0.000 claims description 21
- 102000036639 antigens Human genes 0.000 claims description 21
- 108091007433 antigens Proteins 0.000 claims description 21
- 239000000203 mixture Substances 0.000 claims description 20
- 239000013598 vector Substances 0.000 claims description 9
- 229960005486 vaccine Drugs 0.000 claims description 8
- 150000007523 nucleic acids Chemical class 0.000 claims description 7
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 6
- 102000039446 nucleic acids Human genes 0.000 claims description 6
- 108020004707 nucleic acids Proteins 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 230000003612 virological effect Effects 0.000 claims description 4
- 241000700605 Viruses Species 0.000 claims description 3
- 230000028993 immune response Effects 0.000 claims 8
- 241001465754 Metazoa Species 0.000 claims 7
- 241000725303 Human immunodeficiency virus Species 0.000 claims 3
- 208000031886 HIV Infections Diseases 0.000 claims 1
- 208000037357 HIV infectious disease Diseases 0.000 claims 1
- 230000002238 attenuated effect Effects 0.000 claims 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims 1
- 230000000977 initiatory effect Effects 0.000 claims 1
- 230000003472 neutralizing effect Effects 0.000 claims 1
- 230000001717 pathogenic effect Effects 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 5
- 241000700618 Vaccinia virus Species 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 108090000565 Capsid Proteins Proteins 0.000 description 2
- 102100023321 Ceruloplasmin Human genes 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000010600 3H thymidine incorporation assay Methods 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 108010008038 Synthetic Vaccines Proteins 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 210000000991 chicken egg Anatomy 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 229940124551 recombinant vaccine Drugs 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US43370302P | 2002-12-16 | 2002-12-16 | |
| PCT/US2003/039967 WO2004058278A1 (en) | 2002-12-16 | 2003-12-15 | Recombinant vaccine viruses expressing il-15 and methods of using the same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006514549A JP2006514549A (ja) | 2006-05-11 |
| JP2006514549A5 true JP2006514549A5 (cg-RX-API-DMAC10.html) | 2007-03-15 |
Family
ID=32681963
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004563586A Pending JP2006514549A (ja) | 2002-12-16 | 2003-12-15 | Ｉｌ−１５を発現する組換えワクチンウイルスおよびその使用方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US8663622B2 (cg-RX-API-DMAC10.html) |
| EP (1) | EP1575601B1 (cg-RX-API-DMAC10.html) |
| JP (1) | JP2006514549A (cg-RX-API-DMAC10.html) |
| AU (1) | AU2003297155B2 (cg-RX-API-DMAC10.html) |
| CA (1) | CA2510309C (cg-RX-API-DMAC10.html) |
| WO (1) | WO2004058278A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1673458A4 (en) * | 2003-10-15 | 2007-12-12 | Virax Dev Pty Ltd | FOR RETROVIRUS (e.g., HIV) AND CYTOKIN-CODING POXVIRUS VECTOR |
| AU2004281298B2 (en) * | 2003-10-15 | 2010-05-13 | Virax Development Pty Ltd | Poxvirus vector encoding retrovirus (eg HIV) and cytokine |
| DE102004003572A1 (de) | 2004-01-23 | 2005-08-18 | Bavarian Nordic A/S | Monoparamunitätsinducer basierend auf attenuierten Myxomaviren des Kaninchens |
| US20060210537A1 (en) * | 2005-03-17 | 2006-09-21 | Audonnet Jean-Christophe F | Theileria parva DNA vaccines |
| WO2007001677A2 (en) | 2005-05-17 | 2007-01-04 | University Of Connecticut | Compositions and methods for immunomodulation in an organism |
| EP2366787B1 (en) | 2006-01-13 | 2019-12-11 | The Government Of The U.S.A, As Represented By The Secretary, Dept. Of Health And Human Services | Codon optimized IL-15 and IL-15R-Alpha genes for expression in mammalian cells |
| NZ575388A (en) * | 2006-10-06 | 2012-03-30 | Bn Immunotherapeutics Inc | Recombinant modified vaccinia ankara encoding a her-2 antigen and a taxane for use in treating cancer |
| US8586055B2 (en) * | 2007-01-12 | 2013-11-19 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | DNA immunization protocols |
| EP2173378B1 (en) | 2007-06-27 | 2014-03-19 | Admune Therapeutics LLC | Complexes of il-15 and il-15ralpha and uses thereof |
| GB0719509D0 (en) * | 2007-10-05 | 2007-11-14 | Isis Innovation | Molecular adjuvant |
| WO2009135031A1 (en) | 2008-04-30 | 2009-11-05 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic | Substituted il-15 |
| JP5588990B2 (ja) * | 2008-10-31 | 2014-09-10 | トレムアールエックス， インコーポレイテッド | 機械的表皮破壊を介したポックスウイルスベクターによるワクチン接種 |
| US8691502B2 (en) | 2008-10-31 | 2014-04-08 | Tremrx, Inc. | T-cell vaccination with viral vectors via mechanical epidermal disruption |
| WO2011020047A1 (en) | 2009-08-14 | 2011-02-17 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Use of il-15 to increase thymic output and to treat lymphopenia |
| WO2013083254A1 (en) | 2011-12-09 | 2013-06-13 | Bavarian Nordic A/S | Poxvirus vector for the expression of bacterial antigens linked to tetanus toxin fragment c |
| US20160081314A1 (en) | 2014-09-19 | 2016-03-24 | Regeneron Pharmaceuticals, Inc. | Chimeric Antigen Receptors |
| US20190307879A1 (en) * | 2015-12-04 | 2019-10-10 | The Texas A&M University System | Adenovirus-vectored multivalent vaccine |
| US20190069528A1 (en) * | 2016-03-21 | 2019-03-07 | The George Washington University | Engineered human hookworms as a novel biodelivery system for vaccines and biologicals |
| CN109640644B (zh) | 2016-06-03 | 2021-10-26 | 瑞泽恩制药公司 | 表达外源末端脱氧核苷酸转移酶的非人动物 |
| WO2021163874A1 (zh) | 2020-02-18 | 2021-08-26 | 苏州工业园区唯可达生物科技有限公司 | 一种重组病毒载体、包含其的免疫组合物以及用途 |
| CN115287299B (zh) * | 2021-12-29 | 2023-12-29 | 浙江理工大学 | 一种重组溶瘤痘苗病毒的构建方法及其应用 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5833975A (en) * | 1989-03-08 | 1998-11-10 | Virogenetics Corporation | Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence |
| US5843456A (en) * | 1991-03-07 | 1998-12-01 | Virogenetics Corporation | Alvac poxvirus-rabies compositions and combination compositions and uses |
| US5574138A (en) * | 1993-03-08 | 1996-11-12 | Immunex Corporation | Epithelium-derived T-cell factor |
| US6013268A (en) * | 1994-04-22 | 2000-01-11 | Corixa Corporation | Methods for enhancement of protective immune responses |
| CA2201592A1 (en) | 1994-10-03 | 1996-04-18 | The Government Of The United States Of America, Represented By The Secre Tary, Department Of Health And Human Services | Enhanced immune response by introduction of cytokine gene and/or costimulatory molecule b7 gene in a recombinant virus expressing system |
| US6316006B1 (en) * | 1994-11-23 | 2001-11-13 | The United States Of America As Represented By The Secretary Of The Army | Asporogenic B anthracis expression system |
| CN1200037A (zh) * | 1995-10-17 | 1998-11-25 | 韦恩州立大学 | 鸡白细胞介素－15及其用途 |
| EP0803573A1 (en) * | 1996-04-25 | 1997-10-29 | Gesellschaft für Biotechnologische Forschung mbH (GBF) | Polycistronic expression construct with cytokines for multivalent vaccines |
| CA2745736C (en) | 1996-10-23 | 2016-11-22 | The Trustees Of The University Of Pennsylvania | Immunotherapy and improved vaccines |
| IT1297090B1 (it) | 1997-12-01 | 1999-08-03 | Barbara Ensoli | Tat di hiv-1 o suoi derivati, da soli od in combinazione, a scopo vaccinale, profilattico e terapeutico, contro l'aids i tumori e le |
| EP1053343A2 (en) | 1998-02-11 | 2000-11-22 | Maxygen, Inc. | Targeting of genetic vaccine vectors |
| AU3472099A (en) | 1998-04-06 | 1999-10-25 | Nippon Zeon Co., Ltd. | Avian il-15 nucleotides and polypeptides, and methods of immunizing poultry using avian il-15 |
| US6656471B1 (en) * | 1998-11-17 | 2003-12-02 | Board Of Regents, The University Of Texas System | HIV-specific T-cell induction |
| WO2000041508A2 (en) | 1999-01-15 | 2000-07-20 | Mount Sinai School Of Medicine Of The City University Of New York | Combination therapy of cancer by the activation of co-stimulatory molecules expressed by immune cells and cytokines |
| JP2003523365A (ja) * | 2000-01-28 | 2003-08-05 | スタテンズ セーラム インスティテュート | Ｈｉｖ感染の診断及びコントロールのためのｈｉｖペプチド及びそれをエンコードする核酸 |
| CN1635876A (zh) * | 2000-02-04 | 2005-07-06 | 杜克大学 | 人免疫缺陷病毒疫苗 |
| US20040105871A1 (en) * | 2000-03-02 | 2004-06-03 | Robinson Harriet L. | Compositions and methods for generating an immune response |
| US6933377B2 (en) * | 2002-07-29 | 2005-08-23 | Qun Chen | Compositions comprising multiple immunodeficiency virus subunits for inducing an immune response |
-
2003
- 2003-12-15 US US10/538,974 patent/US8663622B2/en not_active Expired - Fee Related
- 2003-12-15 WO PCT/US2003/039967 patent/WO2004058278A1/en not_active Ceased
- 2003-12-15 EP EP03814012.5A patent/EP1575601B1/en not_active Expired - Lifetime
- 2003-12-15 CA CA2510309A patent/CA2510309C/en not_active Expired - Fee Related
- 2003-12-15 AU AU2003297155A patent/AU2003297155B2/en not_active Ceased
- 2003-12-15 JP JP2004563586A patent/JP2006514549A/ja active Pending
-
2014
- 2014-01-15 US US14/156,105 patent/US20140377306A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Hao et al. | Immunization against Zika by entrapping live virus in a subcutaneous self-adjuvanting hydrogel | |
| Knuschke et al. | Immunization with biodegradable nanoparticles efficiently induces cellular immunity and protects against influenza virus infection | |
| JP2019506175A5 (cg-RX-API-DMAC10.html) | ||
| Pan et al. | Induction of mucosal immune responses and protection of cattle against direct-contact challenge by intranasal delivery with foot-and-mouth disease virus antigen mediated by nanoparticles | |
| HU230364B1 (hu) | Simian adenovírus nukleinsav és aminosav-szekvencia, azt tartalmazó vektorok, és eljárások annak alkalmazására | |
| Pham et al. | Exploiting cross-priming to generate protective CD8 T-cell immunity rapidly | |
| JP2008522621A (ja) | 世界的に流行するトリインフルエンザに対して迅速に応答するためのワクチン | |
| JP2013515747A5 (cg-RX-API-DMAC10.html) | ||
| Chai et al. | Mucosal co-immunization with AIM2 enhances protective SIgA response and increases prophylactic efficacy of chitosan-DNA vaccine against coxsackievirus B3-induced myocarditis | |
| Wang et al. | The potential adjuvanticity of quaternized chitosan hydrogel based microparticles for porcine reproductive and respiratory syndrome virus inactivated vaccine | |
| Kang et al. | Chitosan-alginate polymeric nanocomposites as a potential oral vaccine carrier against influenza virus infection | |
| Cox et al. | Non‐lethal viral challenge of influenza haemagglutinin and nucleoprotein DNA vaccinated mice results in reduced viral replication | |
| CN111315409A (zh) | 狂犬病毒疫苗 | |
| Yang et al. | Adjuvant effects of bacterium-like particles in the intranasal vaccination of chickens against Newcastle disease | |
| Gonzalez-Valdivieso et al. | A DNA vaccine delivery platform based on elastin-like recombinamer nanosystems for rift valley fever virus | |
| Sun et al. | A new RNA vaccine platform based on MS2 virus-like particles produced in Saccharomyces cerevisiae | |
| Karuturi et al. | Encapsulation of an EP67-conjugated CTL peptide vaccine in nanoscale biodegradable particles increases the efficacy of respiratory immunization and affects the magnitude and memory subsets of vaccine-generated mucosal and systemic CD8+ T cells in a diameter-dependent manner | |
| Siddoway et al. | Structural stability and antigenicity of universal equine H3N8 hemagglutinin trimer upon release from polyanhydride nanoparticles and pentablock copolymer hydrogels | |
| Carneiro et al. | Vaccine engineering & structural vaccinology | |
| Jones et al. | Biomaterials at the interface of nano-and micro-scale vector–cellular interactions in genetic vaccine design | |
| Behboudi et al. | Crimean-Congo hemorrhagic fever virus vaccine: past, present, and future | |
| Zhang et al. | Nanoparticle-based vaccines against zoonotic viruses: a review | |
| US20240350629A1 (en) | Genetically engineered cell-derived vaccines | |
| Wen et al. | Identification of potential SLA-I-specific T-cell epitopes within the structural proteins of porcine deltacoronavirus | |
| Stromberg et al. | An mRNA vaccine encoding the Ebola virus glycoprotein induces high neutralizing antibody titers and provides strong protection against lethal infections in mouse models |